Warning Letters to Telehealth providers marketing GLP-1 compounded On March 3rd, FDA sent multiple sets of warnings to 30 Telehealth companies offering GLP-1s on their websites warning them to refrain from improperly using a brand when they are not the compounder or claiming equivalency to FDA approved drugs
This precision approach may reduce side effects, improve adherence, and support safer, more effective GLP-1 therapy
At Ethical Aesthetics, we combine in-clinic injectable treatments with medical-grade home skincare to address the dermis, the deep structural layers, and the surface all at once, consistently over time
Some individuals may also experience mild injection site reactions such as redness or itching
We forecast one to two GLP-1 launches annually starting in 2026, with the first oral entrant expected by 2027
The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-/- and LDLr-/- mice by a mechanism that includes inflammatory pathways